Clinical Trials

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Phase 1 Not yet recruiting

Mesothelioma, Malignant, Mesothelioma

NCT07176975 2026-03-31

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

46 enrolled

Solid Tumors

NCT07246863 2026-03-04

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Phase 2 Recruiting

131 enrolled

Phase 1 Active not recruiting

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04735978 2026-02-27

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

123 enrolled

Advanced Solid Tumor

NCT06697197 2026-02-03

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

413 enrolled

Advanced Solid Tumors

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

102 enrolled

Mesothelioma, Malignant

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

542 enrolled

Solid Tumor

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

50 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumor

NCT05163041 2026-01-15

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

200 enrolled

Advanced Solid Tumor

NCT05901285 2025-11-25

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

43 enrolled

385 enrolled 17 charts 4 FDA

Advanced Solid Tumor

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

37 enrolled 32 charts

Phase 1/2 Active not recruiting

Solid Tumor

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05625412 2025-06-13

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

70 enrolled

GenitourinaryOther solid neoplasm

Advanced Solid Tumors

NCT06191796 2025-06-12

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Phase 1 Terminated

25 enrolled

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

NCT03155061 2025-06-05

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

183 enrolled

Advanced or Metastatic Solid Tumors

NCT06535009 2025-06-04

Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors

Phase 1 Terminated

25 enrolled

Solid Tumor

NCT02913313 2025-04-20

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

101 enrolled 34 charts

Broad Solid Tumor

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

1,163 enrolled 33 charts 2 FDA

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Advanced or Metastatic Solid Tumors

NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Phase 1 Terminated

15 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 3 FDA

Mesothelioma

NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

40 enrolled

Advanced Solid Tumor

NCT02261285 2024-05-06

ONO-4538 Phase I Study in Patients With Solid Tumor

18 enrolled 20 charts

Advanced Solid Tumors

NCT02261298 2024-05-03

ONO-4538 Phase I Study in Patients With Solid Tumor

18 enrolled

Advanced Solid Tumors

NCT05581719 2024-04-17

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Phase 1/2 Terminated

14 enrolled

Solid Tumor

NCT05498480 2024-02-20

RELATIVITY-111

6 enrolled

Advanced Solid Tumors

NCT03730337 2023-10-04

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

24 enrolled

Advanced or Metastatic Solid Tumors

NCT04122625 2023-06-12

SMARTPLUS-106

46 enrolled 36 charts

Solid Tumor

NCT02754141 2023-04-05

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

235 enrolled 37 charts

Malignant Solid Tumor

NCT02598960 2023-03-06

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

295 enrolled 28 charts

Solid Tumors

NCT02593786 2022-10-24

CheckMate 077

58 enrolled 31 charts

Solid Tumors

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies